Thursday, September 07, 2017 1:17:11 PM
Nothing precludes you from posting. Except maybe that you continually post misinformation as if it were fact, such as the "fact" that viable companies do not file for BK when in fact it happens more often than you might think.
I have nothing against you. Not sure why you feel differently toward me. Nor do I think that just because we share a difference of opinion on potential outcomes somehow makes me any less qualified to moderate -- I don't remove posts unless they are in violation of the TOS. You seem like you want someone to moderate this board by removing any posts that you disagree with?
My point about you being wrong is that sometimes it is dangerous to always assume you're the smartest person in the room. Clearly those who took your previous posts and speculation as a buy signal are now deeply in the red.
If you were wrong before, is it possible you're wrong again?
I tend to agree with you that a buyout or takeover is more likely than a BK. But, I can also see the many reasons why, from the CEO's perspective, a BK may be the more favorable solution to her current cash flow problem.
I have nothing against you. Not sure why you feel differently toward me. Nor do I think that just because we share a difference of opinion on potential outcomes somehow makes me any less qualified to moderate -- I don't remove posts unless they are in violation of the TOS. You seem like you want someone to moderate this board by removing any posts that you disagree with?
My point about you being wrong is that sometimes it is dangerous to always assume you're the smartest person in the room. Clearly those who took your previous posts and speculation as a buy signal are now deeply in the red.
If you were wrong before, is it possible you're wrong again?
I tend to agree with you that a buyout or takeover is more likely than a BK. But, I can also see the many reasons why, from the CEO's perspective, a BK may be the more favorable solution to her current cash flow problem.
Recent DCTH News
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/15/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:47:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:23:52 PM
- Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference • Business Wire • 05/12/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:12:12 PM
- Delcath Systems Reports First Quarter 2026 Results and Business Highlights • Business Wire • 05/07/2026 12:00:00 PM
- Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 • Business Wire • 05/07/2026 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:12:24 PM
- Delcath Systems to Host First Quarter 2026 Earnings Call • Business Wire • 04/23/2026 12:30:00 PM
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:06:06 PM
